
Vertex Pharmaceuticals Incorporated
VRTXHealthcare|Biotechnology|US
$547.09
+4.59 (+0.85%)
DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87
Financials
Financial Snapshot
Market Cap
$138.67B
Enterprise Value
$140.17B
Revenue (TTM)
$12.99B
Net Income (TTM)
$3.98B
Cash & Investments
$6.30B
Net Cash
-$175.1M
Free Cash Flow (TTM)
$3.20B
Operating CF (TTM)
$3.69B
Debt/Equity
0.31
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.43B | $2.09B | $3.17B | $3.81B | $6.66B | $7.52B | $10.78B | $11.22B | $6.12B | $6.61B | $6.30B | |
| Operating Cash Flow | $236.1M | $844.9M | $1.27B | $1.57B | $3.25B | $2.64B | $4.13B | $3.54B | -$492.6M | $3.63B | $3.69B | |
| Free Cash Flow | $179.5M | $585.5M | $1.17B | $1.49B | $2.99B | $2.41B | $3.93B | $3.28B | -$790.3M | $3.19B | $3.20B | |
| Capital Expenditure | -$56.6M | -$259.4M | -$95.5M | -$75.5M | -$259.8M | -$235.0M | -$204.7M | -$258.4M | -$297.7M | -$437.6M | -$492.3M | |
| Financing Cash Flow | $133.3M | $68.4M | -$71.2M | $126.8M | -$505.3M | -$1.48B | -$67.7M | -$562.2M | -$1.49B | -$2.26B | $3.25B |
R&D Spending
R&D (TTM)
$4.25B
R&D Intensity
32.7%
R&D Growth vs Prior
+13.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.70B | $2.49B | $3.05B | $4.16B | $6.21B | $7.57B | $8.93B | $9.87B | $11.02B | $12.07B | $12.99B | |
| R&D Expense | $1.05B | $1.32B | $1.42B | $1.75B | $1.83B | $3.05B | $2.66B | $3.16B | $3.63B | $3.75B | $4.25B | |
| R&D % of Revenue | 61.6% | 53.2% | 46.5% | 42.1% | 29.5% | 40.3% | 29.7% | 32.0% | 32.9% | 31.1% | 32.7% | |
| SG&A | $432.8M | $496.1M | $557.6M | $658.5M | $770.5M | $840.1M | $944.7M | $1.14B | $1.46B | $1.75B | $2.41B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.70B | $2.49B | $3.05B | $4.16B | $6.21B | $7.57B | $8.93B | $9.87B | $11.02B | $12.07B | $12.99B | |
| Cost of Revenue | $210.5M | $275.1M | $409.5M | $547.8M | $736.3M | $904.2M | $1.08B | $1.26B | $1.53B | $1.81B | $1.87B | |
| Gross Profit | $1.49B | $2.21B | $2.64B | $3.62B | $5.47B | $6.67B | $7.85B | $8.61B | $9.49B | $10.27B | $11.11B | |
| R&D | $1.05B | $1.32B | $1.42B | $1.75B | $1.83B | $3.05B | $2.66B | $3.16B | $3.63B | $3.75B | $4.25B | |
| SG&A | $432.8M | $496.1M | $557.6M | $658.5M | $770.5M | $840.1M | $944.7M | $1.14B | $1.46B | $1.75B | $2.41B | |
| Operating Income | $9.9M | $123.2M | $635.1M | $1.20B | $2.86B | $2.78B | $4.31B | $3.83B | -$232.9M | $4.76B | $4.40B | |
| Interest Expense | $81.4M | $69.3M | $34.1M | $58.5M | $58.2M | $61.5M | $54.8M | $44.1M | $30.6M | $13.3M | $39.3M | |
| Pretax Income | -$67.4M | -$15.7M | $600.2M | $1.39B | $3.12B | $2.73B | $4.23B | $4.38B | $248.5M | $4.64B | $4.76B | |
| Net Income | -$112.1M | $263.5M | $2.10B | $1.18B | $2.71B | $2.34B | $3.32B | $3.62B | -$535.6M | $3.95B | $3.98B | |
| EPS (Diluted) | -0.46 | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 15.54 | |
| EBITDA | $75.5M | $103.3M | $706.8M | $1.56B | $3.28B | $2.92B | $4.44B | $4.61B | $486.3M | $4.87B | $4.97B | |
| Shares Out. (M) | 244.69 | 253.22 | 259.19 | 260.67 | 263.40 | 259.90 | 259.10 | 260.50 | 257.90 | 258.00 | 255.20 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.18B | $1.67B | $2.65B | $3.11B | $5.99B | $6.79B | $10.50B | $10.37B | $4.57B | $5.09B | $4.98B | |
| Short-Term Investments | $250.6M | $423.3M | $518.1M | $699.0M | $670.7M | $729.9M | $274.5M | $849.2M | $1.55B | $1.52B | $1.32B | |
| Total Current Assets | $1.83B | $2.65B | $3.84B | $4.82B | $8.13B | $9.56B | $13.23B | $14.14B | $9.60B | $11.20B | $11.69B | |
| Total Assets | $2.89B | $3.55B | $6.25B | $8.32B | $11.75B | $13.43B | $18.15B | $22.73B | $22.53B | $26.14B | $32.74B | |
| Total Current Liabilities | $792.5M | $807.3M | $1.12B | $1.33B | $1.88B | $2.14B | $2.74B | $3.55B | $3.56B | $3.86B | $5.00B | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.85B | $3.50B | |
| Total Liabilities | $1.56B | $1.50B | $1.81B | $2.23B | $3.06B | $3.33B | $4.24B | $5.15B | $6.12B | $7.48B | $11.83B | |
| Stockholders' Equity | $1.16B | $2.03B | $4.44B | $6.09B | $8.69B | $10.10B | $13.91B | $17.58B | $16.41B | $18.67B | $20.91B | |
| Retained Earnings | -$5.37B | -$5.12B | -$2.99B | -$1.85B | $858.7M | $3.20B | $6.52B | $10.14B | $9.61B | $13.56B | $16.34B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $236.1M | $844.9M | $1.27B | $1.57B | $3.25B | $2.64B | $4.13B | $3.54B | -$492.6M | $3.63B | $3.69B | |
| Capital Expenditure | -$56.6M | -$259.4M | -$95.5M | -$75.5M | -$259.8M | -$235.0M | -$204.7M | -$258.4M | -$297.7M | -$437.6M | -$492.3M | |
| Free Cash Flow | $179.5M | $585.5M | $1.17B | $1.49B | $2.99B | $2.41B | $3.93B | $3.28B | -$790.3M | $3.19B | $3.20B | |
| Investing Cash Flow | $104.5M | -$437.7M | -$202.2M | -$1.24B | $99.4M | -$340.9M | -$321.1M | -$3.14B | -$3.77B | -$945.4M | -$6.87B | |
| Financing Cash Flow | $133.3M | $68.4M | -$71.2M | $126.8M | -$505.3M | -$1.48B | -$67.7M | -$562.2M | -$1.49B | -$2.26B | $3.25B | |
| Issuance of Stock | $68.2M | $344.8M | $289.3M | $343.2M | $264.9M | $102.0M | $186.3M | $134.6M | $114.6M | $127.7M | $151.6M | |
| Repurchase of Stock | $0.00 | $0.00 | -$350.0M | -$192.0M | -$539.1M | -$1.43B | -$172.0M | -$427.6M | -$1.18B | -$2.02B | -$1.30B | |
| Net Debt Issuance | -$6.9M | -$284.7M | -$12.5M | -$29.1M | -$29.0M | -$18.7M | -$85.5M | -$44.9M | -$33.6M | -$5.4M | $4.50B | |
| Stock Based Comp. | $237.7M | $290.7M | $325.0M | $360.5M | $429.5M | $441.4M | $491.3M | $581.2M | $698.5M | $685.9M | $668.6M | |
| Net Change in Cash | $469.2M | $481.5M | $990.7M | $462.4M | $2.87B | $811.2M | $3.71B | -$139.7M | -$5.80B | $515.6M | $40.8M |
Dilution Tracker
Shares Outstanding
253M
5-Year Share Growth
-2.0%
Stock Issuance (TTM)
$151.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 244.69 | 253.22 | 259.19 | 260.67 | 263.40 | 259.90 | 259.10 | 260.50 | 257.90 | 258.00 | 255.20 | |
| Change vs Prior % | — | 3.5% | 2.4% | 0.6% | 1.0% | -1.3% | -0.3% | 0.5% | -1.0% | 0.0% | -1.1% | |
| Stock Issuance | $68.2M | $344.8M | $289.3M | $343.2M | $264.9M | $102.0M | $186.3M | $134.6M | $114.6M | $127.7M | $151.6M | |
| Stock Repurchase | $0.00 | $0.00 | -$350.0M | -$192.0M | -$539.1M | -$1.43B | -$172.0M | -$427.6M | -$1.18B | -$2.02B | -$1.30B | |
| Stock Based Comp. | $237.7M | $290.7M | $325.0M | $360.5M | $429.5M | $441.4M | $491.3M | $581.2M | $698.5M | $685.9M | $668.6M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 87.6% | 88.9% | 86.6% | 86.8% | 88.1% | 88.1% | 87.9% | 87.2% | 86.1% | 85.0% | 85.6% | |
| Operating Margin % | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | 36.7% | 48.2% | 38.8% | -2.1% | 39.4% | 33.9% | |
| Net Margin % | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | 30.9% | 37.2% | 36.7% | -4.9% | 32.7% | 30.6% | |
| EBITDA Margin % | 4.4% | 4.1% | 23.2% | 37.5% | 52.9% | 38.5% | 49.7% | 46.7% | 4.4% | 40.3% | 38.2% | |
| FCF Margin % | 10.5% | 23.5% | 38.5% | 35.9% | 48.2% | 31.8% | 44.0% | 33.2% | -7.2% | 26.5% | 24.7% | |
| ROE % | -9.7% | 13.0% | 47.3% | 19.3% | 31.2% | 23.2% | 23.9% | 20.6% | -3.3% | 21.2% | 20.1% | |
| ROA % | -3.9% | 7.4% | 33.6% | 14.1% | 23.1% | 17.4% | 18.3% | 15.9% | -2.4% | 15.1% | 12.1% | |
| ROIC % | 0.4% | -26.1% | 12.4% | 14.4% | 25.1% | 21.0% | 21.8% | 16.4% | 2.6% | 18.1% | 12.8% | |
| R&D / Revenue % | 61.6% | 53.2% | 46.5% | 42.1% | 29.5% | 40.3% | 29.7% | 32.0% | 32.9% | 31.1% | 32.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.9% | 46.2% | 22.5% | 36.6% | 49.1% | 22.1% | 17.9% | 10.5% | 11.7% | 9.6% | |
| Gross Profit | 64.5% | 48.4% | 19.2% | 37.0% | 51.3% | 22.0% | 17.7% | 9.6% | 10.3% | 8.2% | |
| Operating Income | 102.1% | 1140.4% | 415.4% | 88.5% | 138.5% | -2.6% | 54.8% | -11.0% | -106.1% | 2144.1% | |
| Net Income | 79.9% | 335.1% | 695.8% | -43.9% | 130.4% | -13.6% | 41.8% | 9.0% | -114.8% | 838.1% | |
| EPS (Diluted) | 80.1% | 326.1% | 677.9% | -44.3% | 128.2% | -12.4% | 42.3% | 8.3% | -115.0% | 836.5% | |
| Operating Cash Flow | 164.6% | 257.9% | 50.3% | 23.5% | 107.3% | -18.7% | 56.2% | -14.3% | -113.9% | 837.2% | |
| Free Cash Flow | 143.7% | 226.1% | 100.6% | 27.2% | 100.4% | -19.5% | 63.0% | -16.5% | -124.1% | 504.1% | |
| R&D Expense | 5.2% | 26.4% | 6.9% | 23.9% | 4.3% | 66.8% | -13.0% | 19.1% | 14.8% | 3.4% | |
| SG&A Expense | 14.8% | 14.6% | 12.4% | 18.1% | 17.0% | 9.0% | 12.5% | 20.3% | 28.8% | 19.7% | |
| Total Assets | 15.9% | 22.5% | 76.1% | 33.2% | 41.3% | 14.3% | 35.1% | 25.2% | -0.9% | 16.0% | |
| Book Value / Share | 20.9% | 49.7% | 112.5% | 35.9% | 41.0% | 17.2% | 38.6% | 25.6% | -6.6% | 14.6% | |
| Debt | 1.8% | -27.9% | -3.2% | 12.8% | 40.8% | 3.8% | -7.0% | -10.1% | 116.4% | 121.9% | |
| Diluted Shares | 1.4% | 3.5% | 2.4% | 0.6% | 1.0% | -1.3% | -0.3% | 0.5% | -1.0% | 0.0% |
Valuation
P/E (TTM)34.94
10Y Low / Med / High20.09 / 28.96 / 141.38
P/S10.68
10Y Low / Med / High7.47 / 10.54 / 14.99
P/B6.63
10Y Low / Med / High5.32 / 7.07 / 18.38
EV/EBITDA28.22
10Y Low / Med / High14.51 / 34.46 / 350.92
EV/Revenue10.79
10Y Low / Med / High6.70 / 9.66 / 14.56
P/FCF43.30
10Y Low / Med / High18.84 / 35.87 / 99.95
Intrinsic Value Models (per share)
DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -160.15 | 141.38 | 20.09 | 47.81 | 22.64 | 24.16 | 22.27 | 28.96 | -193.61 | 29.32 | 34.94 | |
| P/S Ratio | 10.54 | 14.99 | 13.83 | 13.50 | 9.90 | 7.47 | 8.28 | 10.62 | 9.41 | 9.60 | 10.68 | |
| P/B Ratio | 15.52 | 18.38 | 9.50 | 9.24 | 7.07 | 5.60 | 5.32 | 5.96 | 6.32 | 6.21 | 6.63 | |
| EV/EBITDA | 233.25 | 350.92 | 56.70 | 34.46 | 17.16 | 17.40 | 14.51 | 20.69 | 207.43 | 23.57 | 28.22 | |
| EV/Revenue | 10.34 | 14.56 | 13.15 | 12.92 | 9.08 | 6.70 | 7.21 | 9.66 | 9.15 | 9.50 | 10.79 |
Analyst Estimates & Quality
Altman Z-Score
8.86
Safe
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $13.25B | $14.68B | $16.52B |
| Net Income | $4.62B | $5.07B | $6.11B |
| EPS | $18.23 | $20.16 | $24.09 |
| # Analysts (EPS) | 15 | 17 | 11 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| KALYDECO | $802.9M | $684.2M | $553.2M | $475.5M | — | — |
| ORKAMBI | $907.5M | $771.6M | $510.7M | $326.0M | — | — |
| SYMDEKO/SYMKEVI | $628.6M | $420.4M | $180.0M | $123.0M | — | — |
| TRIKAFTA/KAFTRIO | $3.86B | $5.70B | $7.69B | $8.94B | $10.24B | $10.31B |
| Manufactured Product, Other | — | — | — | — | $781.5M | $820.1M |
| ALYFTREK | — | — | — | — | — | $837.8M |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Europe | $1.13B | $1.97B | $2.71B | $3.11B | $3.45B | $3.46B |
| UNITED STATES | $4.83B | $5.29B | $5.70B | $6.04B | $6.68B | $7.55B |
| Other, Non U.S. | $249.9M | $313.2M | $525.9M | $719.8M | $881.3M | — |
| Non-US | — | — | — | — | — | $5.45B |